295 related articles for article (PubMed ID: 30156448)
1. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data.
Choong CK; Ford JH; Nyhuis AW; Joshi SG; Robinson RL; Aurora SK; Martinez JM
Headache; 2017 Oct; 57(9):1359-1374. PubMed ID: 28581025
[TBL] [Abstract][Full Text] [Related]
3. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
[TBL] [Abstract][Full Text] [Related]
4. Real-world health plan claims analysis of differences in healthcare utilization and total cost in patients suffering from cluster headaches and those without headache-related conditions.
Polson M; Lord TC; Evangelatos TM; Lopes M; Santaniello BL
Am J Manag Care; 2017 Nov; 23(16 Suppl):S295-S299. PubMed ID: 29144719
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
6. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
7. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre.
Negro A; Sciattella P; Spuntarelli V; Martelletti P; Mennini FS
J Headache Pain; 2020 May; 21(1):44. PubMed ID: 32366217
[TBL] [Abstract][Full Text] [Related]
9. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
11. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
[TBL] [Abstract][Full Text] [Related]
12. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
14. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
[No Abstract] [Full Text] [Related]
15. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
[TBL] [Abstract][Full Text] [Related]
16. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
17. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
19. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]